Mood and anxiety disorders in patients with multiple sclerosis

International Journal of Psychiatry in Clinical Practice

Volumn 12, Issue 1, 2008, Pages 19-24

  Uguz, Faruk ^a   Akpinar, Zehra ^a   Ozkan, Ishak ^b   Tokgoz, Serhat ^a  

^a SELCUK UNIVERSITY   (Turkey)

^b Department of Psychiatry   (Turkey)

Author keywords

Anxiety; Depression; Multiple sclerosis; Prevalence; Psychiatric disorders

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL FEATURE; DEMOGRAPHY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE EXACERBATION; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MULTIPLE SCLEROSIS; OBSESSIVE COMPULSIVE DISORDER; PHOBIA; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; REMISSION;

EID: 45849090694     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500701330825     Document Type: Article

References (44)

1. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C, Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001;7:340-4.
2. Janssens ACJW, van Doorn PA, de Boer JB, van der Meché FGA, Passchier J, Hintzen RQ. Impact of recently diagnosed multiple sclerosis on quality of life, anxiety, depression and distress of patients and partners. Acta Neurol Scand 2003;108:389-95.
3. Miller A, Dishon S. Health-related quality of life in multiple sclerosis: The impact of disability, gender and employment status. Qual Life Res 2006;15:259-71.
4. Figved N, Klevan G, Myhr KM, et al. Neuropsychiatric symptoms in patients with multiple sclerosis. Acta Psychiatr Scand 2005;112:463-8.
5. Kaya N, Akp?nar Z, Çilli AS. Relationship between depression and anxiety and quality of life in multiple sclerosis. Anatolian J Psychiatry 2003;4:220-5 (Turkish).
6. Galeazzi GM, Ferrari S, Giaroli G, et al. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurol Sci 2005;26:255-62.
7. Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol Med 1989;19:887-95.
8. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry 2005;76:469-75.
9. Sadovnick AD, Remick RA, Allen J, et al. Depression and multiple sclerosis. Neurology 1996;46:628-32.
10. Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen Hosp Psychiatry 1987;9:426-34.
11. Minden SL, Schiffer RB. Affective disorders in multiple sclerosis. Review and recommendations for clinical research. Arch Neurol 1990;47:98-104.
12. Janardhan V, Bakshi R. Quality of life in patients with multiple sclerosis: the impact of fatigue and depression. J Neurol Sci 2002;205:51-8.
13. Lobentanz IS, Asenbaum S, Vass K, et al. Factors influencing quality of life in multiple sclerosis patients: disability, depressive mood, fatigue and sleep quality. Acta Neurol Scand 2004;110:6-13.
14. Möller A, Wiedemann G, Rohde U, Backmund H, Sonntag A. Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand 1994;89:117-21.
15. Chwastiak L, Ehde DM, Gibbons LE, Sullivan M, Bowen JD, Kraft KH. Depressive symptoms and severity of illness in multiple sclerosis: Epidemiologic study of a large community sample. Am J Psychiatry 2002;159:1862-8.
16. Patten SB, Beck CA, Williams JWA, Barbui C, Metz LM. Major depression in multiple sclerosis. A population-based perpective. Neurology 2003;61:1524-7.
17. Patten SB, Lavorato DH, Metz LM. Clinical correlates of CES-D depressive symptom ratings in an MS population. Gen Hosp Psychiatry 2005;27:439-45.
18. Chwastiak LA, Gibbons LE, Ehde DM, et al. Fatigue and psychiatric illness in a large community sample of persons with multiple sclerosis. J Psychosom Res 2005;59:291-8.
19. Williams RM, Turner AP, Hatzakis M, Bowen JD, Rodriquez AA, Haselkorn JK. Prevalence and correlates of depression among veterans with multiple sclerosis. Neurology 2005;64:75-80.
20. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
21. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical ?nterview for DSM-IV. Clinical version (SCID-I/CV). Washington, DC: American Psychiatric Press; 1997.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983;33:1444-52.
23. Regier DA, Farmer ME, Rae DS, et al. One-month prevalence of mental disorders in the United States and sociodemographic characteristics: the Epidemiologic Catchment area Study. Acta Psychiatr Scand 1993;88:35-47.
24. Vicente B, Kohn R, Rioseco P, Saldivia S, Baker C, Torres S. Population prevalence of psychiatric disorders in Chile: 6-month and 1-month rates. Br J Psychiatry 2004;84:299-305.
25. Wittchen HU, Essau CA, von Zerssen D, Krieg JC, Zaudig M. Lifetime and six-month prevalence of mental disorders in the Munich follow-up study. Eur Arch Psychiatry Clin Neurosci 1992;241:247-58.
26. Canino GJ, Bird HR, Shrout PE, et al. The prevalence of spesific psychiatric disorders in Puerto Rico. Arch Gen Psychiatry 1987;44:727-35.
27. Robins LN, Helzer JE, Weissman MM, et al. Lifetime prevalence of spesific psychiatric disorders in three sites. Arch Gen Psychiatry 1984;41:949-58.
28. Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSMIV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
29. Smith SJ, Young CA. The role of affect on the perception of disability in multiple sclerosis. Clin Rehabil 2000;14:50-4.
30. Wilhelm K, Mitchell P, Slade T, Brownhill S, Andrews G. Prevalence and correlates of DSM-IV major depression in an Australian national survey. J Affect Disord 2003;75:155-62.
31. Ohayon MM, Priest RG, Guilleminault C, Caulet M. The prevalence of depressive disorders in the United Kingdom. Biol Psychiatry 1999;45:300-7.
32. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a National Community Sample: The National Comorbidity Survey. Am J Psychiatry 1994;51:979-86.
33. Feinstein A, Feinstein K. Depression associated with multiple sclerosis. Looking beyond diagnosis to symptom expression. J Affect Disord 2001;66:193-8.
34. Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorder and multiple sclerosis. Arch Neurol 1987;44:376-8.
35. Faravelli C, Degl'Innocenti BG, Giardinelli L. Epidemiology of anxiety disorders in Florence. Acta Psychiatr Scand 1989;79:308-12.
36. Dalos NP, Rabins PV, Brooks BR, O'Donnell P. Disease activity and emotional state in multiple sclerosis. Ann Neurol 1983;13:573-7.
37. McCabeMP. Mood and self-esteem of persons with multiple sclerosis following an exacerbation. J Psychosom Res 2005;59:161-6.
38. Zorzon M, Zivadinov R, Nasuelli D, et al. Depressive symptoms and MRI changes in multiple sclerosis. Eur J Neurol 2002;9:491-6.
39. Feinstein A, Roy P, Lobaugh N, Feinstein K, O'Connor P, Black S. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004;62:586-90.
40. Derache N, Marié RM, Constans JM, Defer GL. Reduced thalamic and cerebellar rest metabolism in relapsing-remitting multiple sclerosis, a positron emission tomography study: Correlations to lesion load. J Neurol Sci 2006;245:103-9.
41. Tsukada N, Miyagi K, Matsuda M, Yanagisawa N, Yone K. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 1991;104:230-4.
42. Mikova O, Yakimova R, Bosmans E, Kenis G, Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol 2001;11:203-8.
43. Caggiula M, Batocchi AP, Frisullo G, et al. Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 2005;62:176-82.
44. Brebner K, Hayley S, Zacharko R, Merali Z, Anisman H. Synergistic effects of interleukin-1 β, interleukin-6, and tumor necrosis factor-α: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000;22:566-80.